Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma

被引:49
|
作者
Krieger, D. A. [1 ]
Hudgins, P. A. [2 ]
Nayak, G. K. [7 ]
Baugnon, K. L. [2 ]
Corey, A. S. [2 ]
Patel, M. R. [3 ]
Beitler, J. J. [3 ,4 ,5 ]
Saba, N. F. [5 ]
Liu, Y. [6 ]
Aiken, A. H. [2 ]
机构
[1] Hackensack Univ Med Ctr, Dept Radiol, Hackensack, NJ USA
[2] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA USA
[3] Emory Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Atlanta, GA USA
[4] Emory Univ, Sch Med, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA USA
[5] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[6] Emory Univ, Sch Med, Dept Biostat, Winship Canc Inst, Atlanta, GA USA
[7] NYU, Dept Radiol, Sch Med, 560 1st Ave, New York, NY 10016 USA
关键词
SURVEILLANCE PET/CT; CANCER; UTILITY;
D O I
10.3174/ajnr.A5157
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: The Head and Neck Imaging Reporting and Data System (NI-RADS) surveillance template for head and neck cancer includes a numeric assessment of suspicion for recurrence (1-4) for the primary site and neck. Category 1 indicates no evidence of recurrence; category 2, low suspicion of recurrence; category 3, high suspicion of recurrence; and category 4, known recurrence. Our purpose was to evaluate the performance of the NI-RADS scoring system to predict local and regional disease recurrence or persistence. MATERIALS AND METHODS: This study was classified as a quality-improvement project by the institutional review board. A retrospective database search yielded 500 consecutive cases interpreted using the NI-RADS template. Cases without a numeric score, non-squamous cell carcinoma primary tumors, and primary squamous cell carcinoma outside the head and neck were excluded. The electronic medical record was reviewed to determine the subsequent management, pathology results, and outcome of clinical and radiologic follow-up. RESULTS: A total of 318 scans and 618 targets (314 primary targets and 304 nodal targets) met the inclusion criteria. Among the 618 targets, 85.4% were scored NI-RADS 1; 9.4% were scored NI-RADS 2; and 5.2% were scored NI-RADS 3. The rates of positive disease were 3.79%, 17.2%, and 59.4% for each NI-RADS category, respectively. Univariate association analysis demonstrated a strong association between the NI-RADS score and ultimate disease recurrence, with P < .001 for primary and regional sites. CONCLUSIONS: The baseline performance of NI-RADS was good, demonstrating significant discrimination among the categories 1-3 for predicting disease.
引用
收藏
页码:1193 / 1199
页数:7
相关论文
共 50 条
  • [31] Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
    Lasniska, Izabela
    Kolenda, Tomasz
    Teresiak, Anna
    Lamperska, Katarzyna M.
    Galus, Lukasz
    Mackiewicz, Jacek
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (03) : 290 - 303
  • [32] Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma
    Ducoulombier, Agnes
    Guigay, Joel
    Etienne-Grimaldi, Marie-Christine
    Saada-Bouzid, Esma
    CURRENT OPINION IN ONCOLOGY, 2023, 35 (03) : 166 - 177
  • [33] Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Greenhalgh, J.
    Bagust, A.
    Boland, A.
    Fleeman, N.
    McLeod, C.
    Dundar, Y.
    Proudlove, C.
    Shaw, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 49 - 54
  • [34] Therapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma
    Gauduchon, Thibault
    Neidhardt, Eve Marie
    Fayette, Jerome
    CURRENT OPINION IN ONCOLOGY, 2025, 37 (03) : 175 - 183
  • [35] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, Hsiang-Fong
    Huang, Huai-Cheng
    Liao, Bin-Chi
    Hong, Ruey-Long
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [36] Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck
    Mirabile, Aurora
    Miceli, Rosalba
    Calderone, Rosa Gioia
    Locati, Laura
    Bossi, Paolo
    Bergamini, Cristiana
    Granata, Roberta
    Perrone, Federica
    Mariani, Luigi
    Licitra, Lisa
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (06): : 1895 - 1902
  • [37] Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma
    Specenier, Pol
    Vermorken, Jan B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (09) : 901 - 915
  • [38] Prognostic Factors in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Haring, C. T.
    Rosko, A.
    Heft-Neal, M. E.
    Shuman, A.
    Brenner, J. C.
    Worden, F.
    Spector, M. E.
    Swiecicki, P. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1177 - 1177
  • [39] Vinorelbine and carboplatin in recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Kornek, V
    Scheithauer, W
    Glaser, C
    Toth, J
    Duman, M
    Formanek, M
    Hejna, M
    Kornfehl, J
    ONCOLOGY, 1999, 56 (01) : 24 - 27
  • [40] RADIOTHERAPY FOR POSTOPERATIVE RECURRENT SQUAMOUS-CELL CARCINOMA IN HEAD AND NECK
    DEUTSCH, M
    LEEN, R
    PARSONS, JA
    MERCADO, R
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1973, 98 (05) : 316 - 318